7th Jun 2022 19:03
ValiRx PLC - Nuneaton, England-based drug development company - Widens pretax loss in 2021 to GBP1.7 million from GBP1.5 million the previous year. Research and development costs rise 32% to GBP303,789 in the year from GBP230,115 a year prior. Total assets at December 31 fall to GBP3.5 million from GBP4.9 million at the end of 2020. Chief Executive Suzanne Dilly says the work completed during 2021 has provided a "strong foundation" for the company moving forward. Read More
